Get all your news in one place.
100's of premium titles.
One app.
Start reading
Benzinga
Benzinga
Business
Dylan Berman

What's Going On With Novo Nordisk Shares Monday?

Novo Nordisk

Novo Nordisk A/S (NYSE:NVO) shares are trading higher Monday after the company announced European Union approval for oral semaglutide to reduce cardiovascular death, heart attack and stroke.

What To Know: : The European Medicines Agency's Committee for Medicinal Products for Human Use approved an update to the Rybelsus (oral semaglutide) label to reflect cardiovascular benefits demonstrated in the SOUL trial. The phase 3b study showed Rybelsus reduced the risk of major adverse cardiovascular events — a composite of cardiovascular death, heart attack and stroke — by 14% versus placebo in adults with type 2 diabetes at high cardiovascular risk.

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.